Accelerate Naïve & Engineered Exosome Development through Advanced Purification, Biology & Production Consistency for Translation to Clinical Success & GMP Compliant Scalability

Now more than ever, exosome and extracellular vesicles (EV) therapies are on the verge of groundbreaking clinical and commercial breakthroughs. With recent milestones like Aegle Therapeutics' clinical advances, Capricor Therapeutics' collaboration on a COVID vaccine with the NIH, and NurExone Biologics' innovations in CNS treatments. In September the 6th Exosome-Based Therapeutics Development Summit delved into groundbreaking advancements, access exclusive clinical data, and forge pivotal partnerships to define the future of exosome drug development.

Spanning the complete development cycle of exosome therapeutics from discovery through IND filing, this summit uniquely integrated cutting-edge research with practical commercialization strategies. It stands as the sole industry meeting that bridges the gap between science and business, propelling clinical advancements.

This summit united leading experts from large pharma, biotechs, and academics. They discussed invaluable insights, placed their work at the forefront of pharmaceutical innovation, and advanced their exosome and EV candidates with meaningful partnerships and commercialization for 2024 and beyond.